SEC Form 4 · accession 0001209191-18-002443
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Jan 3, 2018
Accepted (ET)
Jan 5, 2018 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 3, 2018 | M | 6,000 | $5.5004 | A | 21,977 | D | |
| Common StockF2 | Jan 3, 2018 | S | 2,500 | $179.5801 | D | 19,477 | D | |
| Common StockF3 | Jan 3, 2018 | S | 2,468 | $180.362 | D | 17,009 | D | |
| Common StockF4 | Jan 3, 2018 | S | 757 | $181.7018 | D | 16,252 | D | |
| Common StockF5 | Jan 3, 2018 | S | 275 | $182.3591 | D | 15,977 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $5.5004 | Jan 3, 2018 | M | 6,000 | D | — | Jan 16, 2023 | Common Stock | 6,000 | 73,151 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.
- F2The range of prices for the transaction reported on this line was $179.00 to $179.95. The average weighted price was $179.5801. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The range of prices for the transaction reported on this line was $180.00 to $180.85. The average weighted price was $180.3620. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The range of prices for the transaction reported on this line was $181.05 to $182.00. The average weighted price was $181.7018. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5The range of prices for the transaction reported on this line was $182.20 to $182.45. The average weighted price was $182.3591. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of April 1, 2013. The shares underlying these options vested as follows: 25% vested on April 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years